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Abstract
Though significant clinical advances have been made, lung cancer remains 
the most lethal, with a low 5-year survival rate. The variability in patient 
response towards therapy is substantial and is associated with lung cancer’s 
genomic landscape. Pharmacogenetic studies have deciphered many clinically 
relevant associations between tumor genetic alterations and their influences 
on drug efficacy, toxicity sensitivity and overall outcomes of cancer treatment. 
Biomarkers are tools in the arsenal that can help in the prediction, prognosis, 
diagnosis and follow-up of cancer treatment. Bulk and single-cell next-generation 
sequencing of large patient cohorts have generated a better understanding of the 
genetic underpinnings of lung cancer, and opening up personalized therapeutic 
opportunities. Immunotherapy and personalized medicine are providing hope for 
lung cancer patients. This review highlights the genetic alterations and important 
lung cancer biomarkers. The pharmacogenetic associations, personalized 
immunotherapy and challenges associated with effective therapy are also discussed. 
Pharmacogenetics and pharmacogenomics can open up new vistas for optimized, 
personalized NSCLC treatment.
Keywords: Lung cancer, NSCLC, Pharmacogenetics, Biomarkers, Personalized 
medicine, Tyrosine kinase inhibitors, Immunotherapy, Checkpoint inhibitor, 
Challenges
1. Introduction
Lung cancer is the principal cause of cancer-related death worldwide and 
affects both smokers and non-smokers [1]. Men have the highest incidence and 
mortality related to lung cancer, while in women, it is third by incidence and second 
by mortality. With exceptions, the five-year survival rate of lung cancer patients 
is between 10 and 20%, the lowest among most cancer types [2]. Histologically 
80–85% of lung cancers are classified as non-small cell lung cancer (NSCLC), while 
the remaining is small cell lung cancer (SCLC). Adenocarcinoma (LUAD; ~ 65%), 
squamous cell carcinoma (LUSC; ~ 30%), and large cell carcinoma (LCLC) are the 
major subtypes of NSCLC and originates from different types of lung cells [1, 3, 4]. 
While SCLC is less frequent but more aggressive as compared to LUAD and LUSC. 
NSCLC is mainly treated by surgery, chemotherapy, radiation, or targeted therapy 
but with dismal lung cancer survival outcomes. There has been extensive progress 
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in aiming targeted drug delivery towards cancer cells; the accuracy, efficacy, and 
success are often limited by resistance developed by tumor cells and inter-subject 
variability. Low therapeutic indices, differences in health effects, and toxicity from 
chemotherapeutic agents are some of the drawbacks of current NSCLC treatment. 
This has prompted researchers to explore other cancer treatment options, keeping 
in mind individual patient’s genetic responses and adverse drug reactions (ADR) to 
chemotherapeutic agents as ‘pharmacogenetics’ studies [5].
Pharmacogenetics is an evolving branch of pharmacology that examines the 
genetic variation between individuals and its correlation with their response to 
drugs/pharmaceuticals and other xenobiotics. In comparison, pharmacogenomics 
encompasses all genes in the genome that modulates drug response. The awareness 
of the genetic heterogeneity in oncology is of significant importance, owing to 
the limited therapeutic index of cancer therapies and the possibility of ADR-
associated life-threatening complications. Within an individual and comparison 
among NSCLC patients, genomic alterations are major reasons for variations 
in chemotherapeutic drug response and related toxicity [6]. Studies on NSCLC 
genetic and molecular alterations provide new targets for treatment, help in the 
identification of biomarkers for early diagnosis, and helps to predict patient 
prognosis and progression [7]. NSCLC genetic polymorphism can act as either 
predictive or prognostic markers [8]. Single-nucleotide polymorphisms (SNPs) or a 
single nucleotide substitution can affect the expression or functionality of essential 
enzymes and/or targets in the metabolism and activity of anticancer drugs. Genetic 
polymorphism is extensively investigated as a prognostic or predictive factor in 
various tumor types, including NSCLC [9].
Further, pharmacogenetics also helps to prevent cancer-related mortalities 
by forecasting pre-symptomatic diagnosis, designing customized or tailor-made 
dosage regimens for individuals, and optimization of a therapeutic window of 
antineoplastic drugs on a personalized basis. However, pharmacogenetics is an 
evolving arena in cancer treatment and has obvious underlying limitations that 
need to be investigated. Determination of genetic variants has primarily relied 
on SNP, although lately, haplotypes of SNPs and non-genetic factors (like age, 
lifestyle, diet, profession, and intestinal microflora) are included in studies. 
Nonetheless, an additional challenge in pharmacogenetics for treating NSCLC 
deals with validation and standardization of genotyping procedures that are a 
major deciding factor in the personalization of cancer therapy. Many therapeutic 
interventions can be utilized for pharmacogenetics-associated NSCLC treatment. 
The examples include, but not restricted to chemotherapeutic agents (cisplatin, 
gemcitabine, pemetrexed, taxanes, etc.), immune checkpoint inhibitors [pro-
grammed cell death 1 (PD-1), cytotoxic T-lymphocyte protein 4 (CTLA-4)], and 
a combination of immunotherapy with chemotherapy [10]. This chapter throws 
light on the current status of pharmacogenetics-based therapeutics in NSCLC with 
a focus on genetic alterations by gene mutations, exploration of possible treatment 
modalities, challenges involved, and prospects of pharmacogenetics in treat-
ing NSCLC.
2. Gene mutation in NSCLC and Pharmacogenetics
Human Genome Project (HGP) has revealed that the genetic composition of 
humans is 99% similar, with only 1% variations leading to individual differences. 
This clarifies why individuals show a difference in response to anticancer drugs 
concerning drug pharmacology, toxicity, and controlling proliferation, invasion, 
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and metastasis of tumor cells in NSCLC [11, 12]. Simultaneously, several studies 
have suggested a personalized medicine approach to achieving maximum 
efficacy and minimum toxicity of anticancer drugs using pharmacogenetics to 
target NSCLC [12]. Thus, NSCLC patients’ categorization based on underlying 
genetic and molecular alterations can help in personalizing anticancer drugs 
and dosage regimens. Therapy tuned to individual patient’s genotypic and 
phenotypic landscape can achieve the highest therapeutic benefits [13]. The 
complete knowledge of driver mutation pathways and biomarkers can explain 
NSCLC heterogeneity for identifying personalizing therapies. Information about 
driver mutation frequency and associated functional changes can help decipher 
actionable, personalized molecular targets. Therefore, a brief description of the 
critical driver genes that frequently undergo mutations-associated with lung cancer 
(Figure 1).
NSCLC is a heterogeneous disease, and recent sequencing studies have revealed 
the genomic landscape (Figure 1). Common genomic alterations in LUAD include 
KRAS, EGFR, HER2, MET, RET, ALK, and ROS1, while the important alteration 
in tumor suppressor includes TP53, KEAP1, LKB1, and NF1 (Figure 1) [1, 14]. 
Interestingly the major genomic alterations in LUSC include TP53, PIK3CA, CDKN2A, 
NFE2L2, KEAP1, SOX2, PTEN, CDKN2A, RB1, CCND1, NOTCH1, MLL2, and 
HLA-A (Figure 1) [1, 15] (Figure 1). Inhibitors of these genes are primarily used as 
a treatment procedure and as one of the targeted therapies. Several driver oncogenes 
involved in NSCLC have been identified to be targeted with prior information of 
molecular testing and individual patient’s pharmacogenetics towards drugs employed. 
Examples of such targets include EGFR, ALK, KRAS, BRAF, ROS 1, PTEN, HER 2, 
MET, and FGFR, identified in some patient subsets of NSCLC as potential treatment 
targets [16].
Figure 1. 
Comparison of genetic changes in major oncogenic pathways in individuals with LUAD, LUSC, and SCLC 
and the frequencies are shown in the specific boxes. The genetic alterations data is a sum of somatic defects, 




2.1 Epidermal growth factor receptor (EGFR)
EGFR (HER1 in humans) is part of the ErbB family of receptor tyrosine kinases 
(RTKs). Intracellular signaling occurs when RTKs are bound extracellularly to 
form homo or heterodimers [17]. Clinically significant mutations occur within 
the tyrosine kinase domain and are associated with drug sensitivity. The genetic 
alteration, including mutation or amplification in EGFR, results in increased 
tumoral metastasis, angiogenesis, and proliferation. Multiple mutations in the 
EGFR tyrosine kinase domain (deletion exon 19, L858R in exon 21) are associated 
with NSCLC. ATP-competitive TKIs bind to EGFR and yield promising clinical 
outcomes. Though targeted therapy for most EGFR mutations has produced better 
clinical outcomes, T790M mutation inhibition in EGFR resulted in resistance to 
targeted therapy [18]. Three generations of TKI have been reported for personalized 
NSCLC precision therapy based on patient pharmacogenetics; first-generation 
examples being gefitinib and erlotinib, second-generation Afatinib, and Neratinib 
while the third generation includes osimertinib [12]. Afatinib is an irreversible TKI, 
which has a unique property that, unlike other TKIs it does not require CYP3A4 
activity in the liver for its targeted anticancer action. Thus, NSCLC patients with 
pharmacogenetics of deficient or abnormal CYP3A4 activity can be treated with 
afatinib over other established TKIs [19].
2.2 Anaplastic lymphoma kinase (ALK) and ROS Proto-Oncogene 1 (ROS 1)
A fusion gene of anaplastic lymphoma kinase (ALK) with echinoderm 
microtubule-associated protein-like 4 (EML4) (EML4-ALK) is prevalent in 3–5% 
NSCLC patients. EML4-ALK variants act as driver mutations and modulate the 
JAK/STAT, PI3K/AKT, and MAPK pathways, thereby provide proliferative and 
survival advantages to the cancer cells. Crizotinib blocks the kinase activity of the 
EML4-ALK and induces cancer cell apoptosis. ALK fusion is also familiar with other 
genes, including HIP1, KIF5B, KLC1, DCTN1, PTPN3, STRN, and show association 
with NSCLC. Individuals with NSCLC having significant ALK rearrangements 
can be genetically identified with advanced techniques like comprehensive next-
generation sequencing (NGS), immunohistochemistry, and in-situ fluorescence 
hybridization (FISH). In advanced NSCLC stages, ALK TKIs have confirmed 
the progression-free survival of patients with better prognoses. Several second-
generation ALK inhibitors can help target ALK-positive NSCLC, such as alectinib, 
ceritinib, and AP26133 developed and are currently under evaluation in clinical 
trials [20]. ROS1 rearrangements are observed in 1–2% of NSCLC patients. ROS 
1 is a receptor tyrosine kinase and is structurally homology to ALK protein and 
serves as the basis of using ALK inhibitors to target ROS1+ NSCLCs. Crizotinib and 
entrectinib are FDA approved and show a quick positive response by slowing cancer 
progression in ROS-1+ NSCLC [21].
2.3 BRAF
BRAF encodes a threonine/serine protein kinase that is an effector protein 
of KRAS. BRAF activates the MAPK signal transduction, which regulates cell 
proliferation and survival. Mutations in BRAF are about 1 to 3% in NSCLC, with a 
predominance of V600E (50%), G469A (39%), D594G (11%), and K601E, G469S, 
G596R, G466R, and T599dup [21]. Dabrafenib is a BRAF inhibitor combined 
with trametinib (MEK inhibitor), is FDA approved for BRAF V600E+ metastatic 
NSCLC. Vemurafenib, another BRAF inhibitor, showed a 42% overall response rate 
for BRAF V600E+ NSCLC in a basket trial.
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2.4 Kristen Rat Sarcoma Viral oncogene (KRAS)
KRAS encodes a G protein and is a member of the RAS proto-oncogene family. 
KRAS-GTP complex activates the RAS/MAPK, PI3K/mTOR, and RalGDS-RalA/B 
signaling pathways and regulates cell proliferation, differentiation, and survival. 
Mutations in KRAS are recurrent in NSCLC (25–40%), especially LUAD. Ras gene 
and three forms are present H-Ras, N-Ras and K-Ras. In general, KRAS mutations 
have a poor prognosis. Out of KRAS mutations, G12C, G12V, G12D, and G12A are 
common and more frequent in male smokers. Common mutation among smokers 
is G12C (about 41%), while in nonsmokers, it is G12D (56%) and G12V. Though 
compounds are discovered that target the GDP-binding pocket (ARS-853, SML-
8-73-1) but the efficacy and toxicity have been a hurdle. Currently, there is no 
specific developed FDA-approved anticancer agent that uniquely targets KRAS; 
however, MEK and PI3K/mTOR/MEK inhibitors are thought to be selective in the 
inhibiting downstream targets of KRAS mutant cases [22]. KRAS gain-of-function 
mutations serve as predictive markers for NSCLC chemotherapy, but recent studies 
present a geographical bias. KRAS mutations are frequent amongst westerns (30%) 
compared to Asian (10%) LUAD patients [23]. Moreover, the prognostic and 
predictive response is more efficient in LUAD than other NSCLC subtypes, and 
proper clinical pharmacogenetic evaluation and implementation is needed.
2.5 Receptor 2 of the human epidermal growth factor (HER2)
HER2 (ERBB2) is a proto-oncogene, encodes for tyrosine kinase receptors, and 
relies on heterodimerization for activation with receptors from the EFGR family. 
Upon activation, HER2, in turn, triggers downstream signaling like PI3K/mTOR, 
RAF/MEK/ERK, and the MEK/JNK pathways and regulates cell proliferation, 
differentiation, and migration. HER2 genetic alteration not only drives several 
tumors (breast and gastric cancer) but also plays a crucial role in NSCLC formation. 
HER2 amplification and overexpression are associated with 7–34.9% of NSCLCs 
and are related to poor prognosis. Activating mutations (like HER exon 20) are 
observed in 2–4% of NSCLCs cases, especially in LUAD [24]. The mutations in the 
tyrosine kinase domain are investigated as attractive therapeutic targets in NSCLC. 
Targeted therapy against HER2 (TKIs and antibody) is under clinical investigation, 
and the value of HER2 for such patient screening is gaining precedence. 
HER2-targeted TKIs, include afatinib, ipatinib, neratinib, and pyrotinib, while 
trastuzumab and T-DM1 conjugate are antibody-based [25].
2.6 REarranged during Transfection (RET)
RET proto-oncogene encodes for an RTK, localized to chromosome 10, and acti-
vates replication, cell proliferation, motility and differentiation. The GDFN family 
ligand (GFL) interaction with GDFN-family receptor α (GFRα) initiates RET recep-
tor protein dimerization and formation GFL-GFRα-RET heteromeric complex. The 
complex formation results in RET activation and downstream signaling via RAS/
RAF/MEK/ERK or PI3K/AKT1/mTOR pathways. Abnormal RET signaling may lead 
to cancerous growth and have a driver potential. RET Rearrangements are common 
in lung cancers (1–2%). RET fusions are common in NSCLC with partner genes 
like kinesin family member 5B (KIF5B), coiled-coil domain containing 6 (CCDC6), 
tripartite motif-containing 33 (TRIM33), Cut like homeobox 1 (CUX1), nuclear 
receptor coactivator 4 (NCOA4), and KIAA1468 [26]. Selpercatinib, a TKI that is 
FDA approved for use in RET+ NSCLC [27]. Other TKIs like vandetanib, cabozan-
tinib, sorafenib and sunitinib can inhibit activated RET signaling and tumorigenic 
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transformation. Activating RET mutations like M918T and acquired RET mutations 
(G810R, G810S, and G810C) in response to selpercatinib treatment is also reported 
in NSCLC [28]. Thus, RET is an interactive target and a biomarker for NSCLC.
Other actionable biomarkers in the lung include MET, PI3KCA, NTRK1, FGFR2, 
and DDR2 and are explained in detail elsewhere [29]. As driver mutations affect 
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explored for targeted drug therapies towards various mutating genes associated 
with NSCLC, as mentioned in Table 1.
3. Genetic alterations and lung cancer treatment response
NSCLC is a widely prevalent and challenging health problem for the human 
race. Despite rapid advances in lung cancer treatment, it is still one of the leading 
causes of death worldwide. Traditional chemotherapeutic approaches failed to 
yield satisfactory results in terms of treatment outcome. Interestingly, the associa-
tion of genetic variations with treatment outcome of some of the most commonly 
used chemotherapeutic drugs has opened new vistas in the domain of lung cancer 
treatment [12]. The relatively new area of Pharmacogenetics aims to correlate the 
association between genetic variations and drug effects and formulate a rational 
personalized drug treatment offering minimum side effects and maximum efficacy 
[42]. The inherited genetic variations such as single-nucleotide polymorphisms 
(SNPs) have been primarily studied, most commonly focusing on the candidate 
gene approach. These genetic changes can either lead to the altered expression or 
function of drug-metabolizing enzymes or their targets, thereby modulating the 
activity of chemotherapeutics [43].
Pemetrexed is a commonly used folate antimetabolite, a multi-targeted anti-
cancer drug used in NSCLC treatment. Pemetrexed causes inhibition of critical 
enzymes in the folate pathway including, thymidylate synthase, dihydrofolate 
reductase, and glycinamide ribonucleotide formyl transferase leading to a reduc-
tion in folate depletion resulting in altered purines and pyrimidines synthesis [44]. 
Thymidylate synthase (TS) expression is associated with the treatment outcome, 
especially in nonsquamous carcinoma patients treated with pemetrexed-based 
chemotherapy [45]. Studies conducted on the role of polymorphisms in TS, such 
as polymorphic tandem repeats located in the TS enhancer region (TSER), provide 
conflicting results. While some studies have observed that increased expression of 
TS with three copies (TSER*3) of the R than with two copies (TSER*2) is associated 
with treatment outcome in lung cancers, other studies did not observe such an asso-
ciation [46]. However, the homozygous variant T677 T of methylenetetrahydrofo-
late reductase was associated with prolonged progression-free survival compared to 
the wild-type or heterozygous genotype. The observation could be due to increased 
TS inhibition by pemetrexed due to the polymorphic variant since methylenetetra-
hydrofolate reductase is an essential regulator of folate homeostasis.
The entry of pemetrexed into the cells is mediated by the reduced folate carrier 
(RFC). A study investigating the combined action of pemetrexed and bevacizumab 
suggested the role of polymorphisms in RFC exon6 and progression-free survival. 
A similar association was also observed with IVS7 (1478) polymorphism in glutamyl 
hydrolase (GGH) while GGH IVS2 (1307) CC genotype was associated with signifi-
cantly longer overall survival [47]. On the contrary, no association was observed 
with the outcome for GGH IVS7 (1478) and IVS2 (1307) in a randomized phase II 
trial involving fifty four patients for treatment with pemetrexed and gemcitabine 
[48]. The study also reported an association of RFC-exon6-SNP with outcome fol-
lowing treatment with pemetrexed.
The tyrosine kinase inhibitor (TKI) family has been clinically successful as 
an anti-cancer strategy. An enhanced expression of EGFR leads to the activation 
of pathways and proto-oncogenes that can lead to lung cancer development. 
For the EGFR gene, most of the studies have focused on polymorphisms present 
in regions regulating the expression, such as those present in the 5′-flanking 
region and intron-1. Two important SNPs located in the transcriptional start 
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site of the promoter region of EGFR are −191C/A and − 216G/T. The −191C/A 
polymorphism causes enhanced EGFR expression and activity, while the 
−216G/T genotype, located at the binding site for the transcription factor Sp1, 
increases mRNA expression. However, the A-G variant, causing substitution 
of an arginine with a lysine at codon 497 (R497K), leads to the reduction of 
EGFR activity [49]. All three polymorphisms were evaluated for association 
with gefitinib treatment response in advanced NSCLC patients. Out of the 
three polymorphisms, the −216G/T variant showed a significant association 
with prolonged progression-free survival, high rates of stable disease/partial 
response, and treatment-related side effects such as rash and diarrhea [50].
Another EGFR polymorphism present in intron one was also reported to play an 
important role in the treatment outcome of gefitinib for NSCLC in different ethnic 
groups. The dinucleotide polymorphism is associated with a variable number of 
CA repeats in NSCLC. Upon gefitinib-treatment, it was observed that a smaller 
number of CA repeats was associated with increased EGFR transcription and 
better survival. This was observed in both Asian and Caucasian populations. For 
instance, studies conducted in Chinese patients treated with gefitinib reported 
better responses in NSCLC patients with shorter CA repeats (less than 16 repeats) 
[51]. However, the results were inconsistent in Caucasian patients as no association 
was observed for CA repeats and clinical outcomes in patients treated with gefitinib 
[52]. Similar observations were also made in a study involving advanced NSCLC 
patients treated with erlotinib [53].
Genetic polymorphisms in Protein kinase B (AKT1), DNA repair pathway genes 
like ATP-binding cassette superfamily G member 2 (ABCG2) also play an essential 
role in determining the treatment outcome in NSCLC patients. In studies involving 
the Caucasian populations, lower Akt protein levels were observed associated with 
haplotype having two polymorphisms (SNP3 and SNP4). The same haplotype was 
also found associated with lower rates of apoptosis-induction by radiation in EBV-
transformed lymphoblastoid. In another Caucasian study involving NSCLC patients 
treated with gefitinib, AKT1-SNP4 A/A genotype was associated with shorter 
overall survival while AKT1-rs2498804 GT and GG alleles resulted in metastases 
in the brain [54]. Similar observations were also made in a Korean study where 
it was observed that in NSCLC patients, several genetic variations in the PI3K/
AKT pathway served as a useful marker in response to various chemotherapeutic 
drugs [55].
ABCG2 is a member of the ATP-binding cassette (ABC) transporter family 
and plays a crucial role in the absorption and elimination of gefitinib. ABCG2 
binds gefitinib and is expressed at higher levels in the gastrointestinal tract. 
Polymorphisms in ABCG2 could affect the metabolism of gefitinib due to variations 
in expression, function, and localization of ABCG2. One such polymorphism, 
ABCG2 421C/A (Q141K), has been found to be associated with a decreased protein 
expression and associated activity of ABCG2, resulting in the accumulation of both 
gefitinib and erlotinib [56] though conflicting reports are also available.
Investigators have also explored the association of selected genetic variations 
with toxicity caused by EGFR-TKIs, such as rash and diarrhea. In a study involving 
52 NSCLC patients undergoing treatment with gefitinib, different intron-1 CA 
repeat variants were found to be associated with varying grades of skin rash 
[57]. Similarly, studies have also reported the association of genetic variations in 
EGFR and ABCG2 with diarrhea in patients undergoing treatment with gefitinib. 
Examples of such variants are EGFR 191C/A and A/A, EGFR 216G/G, R497K A/A, 
and ABCG2 421C/A variant [50, 58]. However, another study failed to find such 
an association with ABCG2 421C/A, though moderate–severe diarrhea was found 
to be associated with ABCG2 15622C/T polymorphism and the ABCG2 (1143C/T, 
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−15622C/T) haplotype [59]. A category of enzymes that play an essential role 
in the metabolism of chemotherapeutics is cytochrome P450s. Commonly used 
anti-cancer drugs used in the treatment of NSCLC such as gefitinib and erlotinib 
are metabolized by the CYP3A4, CYP3A5, and CYP1A isozymes. However, erlotinib 
but not gefitinib is metabolized by CYP1A2. CYPs also exhibit a large number of 
genetic variations, which results in different pharmacokinetics of TKIs in NSCLC 
patients. In cases undergoing treatment with erlotinib and having skin rash due to 
A/A variant of CYP3A4 resulting in lower CYP3A4 expression [60]. The same study 
also reported the association of CYP3A5*3 G polymorphism with grade ≥ 2 rash and 
diarrhea.
The ALK gene, encoding a TK receptor, gets fused with echinoderm microtubule 
associated protein like 4 (EML4), leading to the development of lung cancer. The 
fusion gene EML4-ALK encodes a fusion protein that leads to the constitutive 
activation of ALK kinase as a result of oligomerization of ALK in absence of the 
ligand. Crizotinib is a commonly used ALK-inhibitor drug that targets lung cancer 
caused as a result of the EML4-ALK fusion protein. It acts as a ATP-competitive 
inhibitor and binds to the ATP binding pocket necessary for kinase activity 
leading to carcinogenesis [61]. The role of ALK gene mutations in determining the 
treatment outcome in lung cancer patients receiving Crizotinib was brought to light 
when it was observed that a male patient of lung cancer developed resistance to the 
drug after an excellent initial response [62].
Further investigations revealed that the cause of resistance was two mutations 
in the ALK gene (C1156Y and L1196M). The observations were validated by an in 
vitro study in which the mutated gene, when transfected into mouse cells, resulted 
in reduced drug sensitivity and enhanced cellular growth when exposed to different 
concentrations of ALK inhibitors. In another study involving 14 ALK-positive 
patients, the same pattern of treatment response was observed. After promising 
initial response to the drug, the patients experienced tumor progression. In this 
study also, the reason for drug resistance was identified as mutations on the ALK 
gene (L1196M and G1269A) along with two more gains of copy number [63]. A 
study by 3D modeling into the insights of mechanisms by which the mutations alter 
crizotinib activity revealed that L1196M, G1202R, S1206Y and 1151insT mutants are 
near the crizotinib-interacting ATP-binding pocket. L1196M worked as a gatekeeper 
mutation as it prevents the interaction between crizotinib and the ATP-binding 
pocket while G1202R and S1206Y decrease affinity to crizotinib by changing the 
solvent-exposed region [64].
4.  Antibodies and immune checkpoint inhibitors in non-small cell lung 
cancer
Apart from the conventional chemotherapeutic agents used for the treatment of 
NSCLC, immune checkpoint inhibitors (ICIs) have gained much attention in recent 
times. Though our immune system can target the cancer cells, yet cancer cells 
escape this immunosurveillance and destruction. The main hallmark of anti-tumor 
immune response is T cell-mediated identification of tumor-specific antigens. 
Tumor cell often activates immune checkpoints to effect an immune escape. 
Programmed cell death protein 1 (PD-1/CD279) and cytotoxic T-lymphocyte pro-
tein 4 (CTLA4) are the best-studied checkpoint inhibitors. Programmed cell death 
ligand-1 (PD-L1) expression, especially by tumor cells, can inhibit the response 
of PD-1 expressing effector T cells and induce T cell exhaustion. Treatment using 
anti-PD-1 or anti-PD-L1 antibody causes checkpoint blockade and thereby releases 
the inhibitory brake on anti-tumor effector T cell function [65, 66]. The approved 
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monoclonal antibodies for targeting PD-1 are nivolumab and pembrolizumab 
while the anti-PDL1 antibodies are atezolizumab and durvalumab for lung cancer 
treatment [67]. The effects of pembrolizumab may be influenced by two possibili-
ties: change in its binding site on the receptor or genetic changes that may reduce 
the immune system’s capability to target cancer cells. A study conducted on cases 
showing resistance against pembrolizumab did reveal mutations that inactivated 
Janus kinase1 (JAK1), Janus kinase2 (JAK2), and β2 microglobulin (B2M). The data 
indicated that the immunological pathways were affected by the mutations [68].
CTLA-4, also known as CD152, is a receptor expressed on the surface of lym-
phocytes and fibroblasts. This receptor on the surface of T lymphocytes competes 
with CD28 (co-stimulatory receptor) to bind to the B7 ligands CD80 and CD86, 
expressed on the surface of antigen-presenting cells. Since the CTLA4 receptor has 
a higher affinity for binding to the B7 ligands, it inhibits the binding of CD28, which 
leads to the decreased production of the cytokine IL-2 and ultimately prevents 
the activity of the Cancer-Immunity Cycle (CIC) [69]. Thus, inhibition of CTLA4 
checkpoint can lead to the suppression of binding between CTLA4 receptor and 
ligand B7. This will boost the clearance of cancer cells by activating the innate and 
adaptive components of the immune system. US FDA has already approved ipilim-
umab and tremelimumab as immune checkpoint inhibitors targeting the CTLA4 for 
patients with metastatic melanoma. Moreover, studies are going on with immune 
checkpoint inhibitors targeting the CTLA4 for NSCLC and may deliver promising 
results [70].
The field of immunotherapy has shown significant advancements in the 
treatment of several cancers, including NSCLC. However, the success is also 
accompanied by serious challenges, particularly in NSCLC. Some NSCLC patients 
show primary resistance and are unresponsive to ICIs, while others develop 
secondary resistance during/after the treatment. Moreover, a unique spectrum of 
immune-related adverse events (IRAEs) also limits the use of ICIs. The mechanism 
governing both the primary and secondary resistance needs further investigation. 
Immunopharmacogenomics can explain these resistance mechanisms. The current 
phase III studies of PD-1 and PD-L1 inhibitors, either alone or in combination with 
conventional approaches in different stages of NSCLC, will serve to improve the 
treatment outcome significantly [1]. However, there are still many challenges ahead 
though immunotherapy with checkpoint inhibitor has already raised new hopes of 
novel treatment modality with better and more effective treatment outcomes for 
NSCLC patients.
5. Challenges in pharmacogenetics in lung cancer
Lung cancer is one of the leading causes of cancer-related death worldwide, 
with a 5-year survival rate of approximately 15%, suggesting a comprehensive 
genomic alteration map may help. The lack of an early diagnosis and inefficiency 
in conventional therapies causes poor prognosis and lung cancer patients’ overall 
survival. Moreover, pharmacogenetic trials ended in conflicting and inconclusive 
data because of non-standardized methodologies, sample heterogeneity, clinical 
sample processing techniques, and the inadequate number of enrolled individuals. 
Clinical sample preparation protocols are varied and challenging to follow in a 
clinical setting. Collection of needle biopsy of lung tumor is a challenge in itself. 
The tumor cores are usually retained as Formalin-Fixed Paraffin-Embedded 
(FFPE) tissue specimens. Defining the normal tissue needs more attention than 
we think. Recent findings suggest that normal-looking tissue adjacent to the 
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tumor may be existing in an intermediate state. Considering tumor variability, it is 
unclear whether core biopsies are indicative of the oligoclonal nature of NSCLC? 
Data generated from specific experiments suggest histological markers can vary 
significantly and therefore contributing to sequence data heterogeneity within 
and amongst various studies. Another aspect related to biomarkers is robustness, 
sensitivity, and false-positive assessment of the molecular diagnostic, especially 
regarding immune checkpoint therapy.
Lack of pharmacogenetics biomarkers is another challenge for NSCLC 
pharmacogenetics. Biomarkers are significant in drug development and are used 
to measure the investigational drug effects on people. Cancer biomarkers are 
essential for diagnosis, risk assessment, the staging of cancer, screening, patient 
stratification, prognosis, and predict the impact of the therapy [71]. The selection 
of cytostatic drugs is based on the estimated responsiveness as per the predictive 
molecular biomarkers. In NSCLC, the predictive biomarkers that are providing 
for targeted therapy include EGFR and ALK. As an example, FDA-approved drugs 
like afatinib are associated with biomarker EGFR, and ceritinib is related to the 
biomarker ALK. Other essential genomic alterations in key genes like KRAS, ROS1, 
MET, NTRK1, FGFR, BRAF, PI3KCA, RET, PTEN, and DDR2 provide valuable 
information (Figure 2). The REMARK (Reporting Recommendations for Tumor 
Marker Prognostic Studies) guidelines provides criterion and suggestions for 
designing prognostic and tumor biomarker studies [72]. Several NSCLC studies 
still do not follow and comply with the standardization protocols of REMARK, 
thus obfuscating the clinical use scenario of biomarkers. Many trials do not include 
biomarker analysis as a criterion for including patients, especially in NSCLC, 
and serves as a significant challenge by creating selection bias. Tumor prognostic 
biomarker staining (for TUBB3) and scoring was done in a fraction of NSCLC in the 
N + IFCT-0002 trial [73].
Immune checkpoint therapy relies on monoclonal antibodies and may mediate 
a variety of adverse hypersensitivities, including anaphylaxis (type I), cytotoxic 
(type II), immune (type III), and T cell-mediated (type IV) reactions [74]. The 
Discovery of predictive biomarkers for immune-associated adverse reactions are 
essential pharmacogenetic needs for personalized cancer therapy. Genetic poly-
morphism, especially in the genes associated with antibody recognition, presenta-
tion, and immune response, may affect the efficacy. The role of polymorphism 
Figure 2. 
Representation of biomarkers and targeting drug acting on the same.
Pharmacogenetics
12
concerning the metabolism of therapeutic antibodies can alter antibody half-life 
and therapeutic response. Genotypic variation in the PD-L1 (rs4143815 C/C and 
C/G genotype in comparison to G/G phenotype) show higher progression-free sur-
vival upon treatment with nivolumab in NSCLC [75]. A study conducted by Rizvi 
et al. showed a correlation of pembrolizumab efficacy with an increased nonsyn-
onymous somatic mutational burden. A higher mutational burden was associated 
with an expanded neo-antigen repertoire and effective T cell-specific response 
[76, 77]. The Discovery of personalized biomarkers for risk assessment, detection, 
diagnostic, prognostic, and monitoring can be crucial in tailored NSCLC therapy. 
Pharmacogenetic studies correlating genetic alterations regarding immunotherapy 
are yet to be correctly established.
6. Future direction and conclusion
In this modern world of fast-growing medicine and research, treatment is not 
just about curing an aliment but also providing a better standard of life and living. 
With new social standards, smoking habits, and environmental pollution, NSCLC 
diagnoses are projected at approximately 116,660 women and 119,100 men in 
2021. To treat lung cancer, it is essential to identify the disease at the earliest. The 
Discovery of NSCLC biomarkers can help identify disease susceptibility and aid 
in disease screening, diagnosis, prognosis, prediction of response, and monitor-
ing disease recurrence. Recent advances in novel detection techniques like high 
throughput omics technology, multiplexed immunofluorescence microscopy, 
bioluminescence resonance energy transfer (BRET), CRISPR-based biosensors, 
surface-enhanced Raman spectroscopy have generated hope for better treatment. 
Bulk and single-cell next-generation sequencing (NGS), circulating cell-free DNA 
(cfDNA), single-cell proteomics can help in biomarker discovery and push modern 
pharmacogenetics and personalized medicine. Discovery strategies including 
hotspot panels (frequently observed gene mutations), Actionable gene panels 
(targeted gene exons), disease-focused panel (genes involved in a disease), com-
prehensive panels (correlative genes), and validated panels (tested genes) NGS 
applications can reduce biomarker discovery time. Machine learning-based data 
analyses platforms and algorithms may help undertake candidate polymorphism 
search; candidate pathway searches better predict correlations between gene altera-
tions and therapeutic response.
Exploring new molecular signature-based personalized medicine can open up 
future potential healthcare environments. Considering the massive expansion in 
NGS-based NSCLC molecular data generation, integrating pharmacogenetics and 
genomic knowledge with the potential of theranostics can lead to effective therapy. 
Theranostics, the fusion of therapeutics and diagnostics, using a nanotechnology-
based delivery platform can pave the way to precision and personalized medicine 
[78]. Nanotechnology is a quickly evolving biomedical research area and has been 
used to address several biological issues, including therapeutics and diagnostics 
[79]. Nanoscale-based delivery platforms like liposomes, polymeric nanoparticles, 
metal nanoparticles, and bio-nano particles can be efficiently used for theranostic 
applications for targeting cancer. Nanoparticle offers a benefit over standard 
medicinal therapies regarding biocompatibility, enhanced permeability retention, 
higher drug loading, targeting precision, a significant degree of versatility, and 
real-time monitoring of the disease [80]. Nanoparticle-based nanotheranostics can 
provide multifunctional benefits including, imaging, prognostic, diagnostics, and 
monitoring therapeutic outcome in NSCLC patients. Mukherjee et al. presented a 
detailed analysis of lung cancer theranostics [4].
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Liquid biopsy and microfluidic technology can help in early disease detec-
tion. NGS has already helped identify new cancer-driving mutations, and this has 
encouraged scientists for drug repurposing. Scientists are deciphering synthetic 
lethality interactions, where two or more gene simultaneous alteration in the pres-
ence of a therapeutic may lead to lethality. Efficacy of immune checkpoint therapies 
is associated with genotypic variance, and immune-based biomarkers may provide 
a clear understanding of immunepharmacogenetics. Big data analyses of the grow-
ing pharmacogenetic or pharmacogenomic dataset can soon lead us to personalized 
NSCLC therapeutics.
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